World J Gastroenterol. 2010 September 7; 16(33): 4130-4134.
Published online 2010 September 7. doi: 10.3748/wjg.v16.i33.4130.
Epstein-Barr virus: Silent companion or causative agent of chronic liver disease?
Mihaela Petrova and Victor Kamburov.
Mihaela Petrova, Clinic of Gastroenterology, Ministry of Interior, Sofia 1606, Bulgaria
Victor Kamburov, Gastroenterology Division, First Multiprofile Hospital for Active Treatment, Sofia 1142, Bulgaria
Author contributions: Petrova M wrote the first draft of the manuscript; Kamburov V contributed to the subsequent drafts and equally to the general idea and structure of the manuscript.
Correspondence to: Dr. Mihaela Petrova, PhD, Clinic of Gastroenterology, Ministry of Interior, MI, 79, “Skobelev” Blvd, Sofia 1606, Bulgaria. mpetrova@gmail.com
Telephone: +359-2-9821356 Fax: +359-2-8964880
Received February 16, 2010; Revised March 22, 2010; Accepted March 29, 2010;
Abstract
The Epstein-Barr virus (EBV) has an important and multifaceted role in liver pathology. As a member of the herpes virus family, EBV establishes a persistent infection in more than 90% of adults. Besides acute hepatitis during primary infection, many clinical syndromes of interest for the hepatologist are associated with EBV infection. The role of EBV in the evolution of chronic hepatitis from hepatotropic viruses is considered. Chronic EBV-associated hepatitis is suspected in immunocompetent adults with compatible serology, suggestive histology and detection of the viral genome in the liver and/or increase of specific circulating cytotoxic T-lymphocytes. EBV is the main cause of post-transplant lymphoproliferative disorders which occur in up to 30% of cases. EBV-driven lymphoproliferative diseases are also recognized in non-immunocompromised patients and liver is involved in up to a third of the cases. Directly implicated in the pathogenesis of different tumors, EBV has a disputable role in hepatocellular carcinoma carcinogenesis. Further research is required in order to establish or reject the role of EBV in human liver cancer. This paper attempts to discuss the range of EBV-associated chronic liver diseases in immunocompetent patients, from mild, self-limiting mononuclear hepatitis to liver cancer.
Keywords: Epstein-Barr virus, Chronic hepatitis, Liver disease, Chronic active Epstein-Barr virus, Post-transplant lymphoproliferative disorder, Infectious mononucleosis
PRIMARY INFECTION, LATENCY AND REACTIVATION
The Epstein-Barr virus (EBV) is a member of the Gammaherpesvirinae subfamily of herpes viruses. It infects more than 90% of the adult population all over the world. EBV shares the tendency of establishing latency in the host with other herpes viruses[1]. Primary infection leads to transitional viremia, followed by a strong T-cell adaptive immune response, which actually holds the infection latent in immunocompetent individuals[2]. Short episodes of spontaneous reactivation and consequent viral replication normally occur in healthy individuals[3]. In the immunocompetent individual the occurrence of EBV reactivation leading to immortalization of B-lymphocytes is strongly regulated by cytotoxic T lymphocytes (CTLs) specific for lytic and latent antigens[4]. It is believed that almost no specific symptoms indicate these events. Viral replication may cause significant clinical entities and even severe complications in patients with diminished cell-mediated immunity[5,6]. The latter refers to immunosuppression, physical or psychological stress, other infections, etc[7].
The EBV DNA encodes more than one hundred proteins expressed during the lytic infection. Only ten of these proteins are expressed in latently infected B-cells in vitro[8]. Limited gene expression during latency ensures successful escape from CTL recognition. However, this has led to sophistication of the diagnostic tools for detection of EBV gene products in different tissues. Different types of latency regarding expression of EBV latent genes are established in different diseases and states. EBV-encoded nuclear antigen 1 (EBNA-1) and small RNAs (EBER) are found in Burkitt’s lymphoma, whereas latency type of Hodgkin’s disease is represented by additional expression of the latent membrane proteins (LMP-1 and LMP-2)[9]. These differences further hamper the diagnosis of EBV-associated disease and challenge both the clinicians and molecular biologists to reveal the causal links.
The classical form of primary EBV infection in the immunocompetent individual is infectious mononucleosis (IM, or first-kiss-disease). Albeit not a challenge for general physicians, in some cases it could be of interest for hepatologists. Almost half of patients with IM have hepatitis, while jaundice is present in 5%-10% of cases[10,11]. Besides transient liver enzyme elevations, cholestatic pattern of severe hepatitis[12-14] and even fatal liver failure might complicate the IM[15-17].
CHRONIC ACTIVE EBV INFECTION
Chronic active EBV infection (CAEBV) is thought to be a rare disorder, defined by chronic severe illness, which begins as a primary EBV infection associated with abnormal EBV serology, histological evidence for organ disease (including hepatitis) and demonstration of EBV gene products in tissue. The CAEBV infection might progress to a chronic or recurrent infectious mononucleosis-like disease[18]. This is a result of a disturbance in the host-virus balance and Th1/Th2 disbalance. It is reported that CAEBV is associated with an aggressive clinical course[19] but the pathogenesis and pathophysiology of CAEBV are still not well characterized. Patients with iatrogenic, congenital, or acquired immunodeficiency are at increased risk for EBV-associated lymphomas and CAEBV. It seems that CAEBV in Western countries is milder than in Asian countries[20]. The mild forms from the Western world are characterized by intact immune control of B-cells, relatively low viremia and EBV-specific CTL expansion comparable to seropositive donors. Under the heading of the popular clinical term CAEBV, novel EBV lymphoproliferative diseases (LPDs) have been identified recently in non-immunocompromised hosts, both in Asian and Western countries. Immune senescence in the elderly is also associated with both reactive and neoplastic EBV-driven LPDs[21]. Almost a third of the patients with some EBV-driven LPDs have liver involvement, and liver failure is an important cause of death in this group[22].
EBV-ASSOCIATED CHRONIC HEPATITIS
Some reports have suggested EBV to be a trigger agent for an autoimmune hepatitis[23]. It should be kept in mind that liver involvement in CAEBV might mislead even experienced physicians to misdiagnose an autoimmune hepatitis (AIH)[24]. Nobili et al[25] identified EBV and hepatitis A virus infections as possible initiating agents in a cohort of AIH type I patients. In similar cases a suppressor T-cell dysfunction and consequent loss of control and raising of ASGRP antibodies have been seen to be involved in the evolution of the viral disease[26-28]. EBV has been suspected as a probable cause of particular granulomas in the liver[29] and even in a rare vanishing bile duct syndrome[30].
In some patients with chronic liver disease caused by a major hepatotropic virus, an infection with other viral agents may be discovered. We previously evaluated patients with chronic hepatitis B and C regarding their EBV serology. Our patients with reactivated EBV infection had lower levels of HBV DNA and higher mean values of serum hepatitis C virus (HCV) RNA respectively, compared to EBV-seropositive patients without reactivation[31]. Several hypotheses were put forward to explain those results. Reactivation of the EBV-specific T cells leads to significant production of several cytokines, especially interferon-? (IFN-?), interleukin (IL)-1, IL-2 and IL-10[32]. Additionally, the EBV BCRF1 shares high sequence homology with human IL-10 and exerts the same activity. Exogenous IL-10 enhances HCV replication[33]. IFN-? inhibits HBV replication in the absence of cell necrosis[34]. It is unclear why the effect on viral replication was opposite in HBV and HCV cases. Most probably, T cell cross-activation could explain the hepatitis virus reactivation. The latter conclusion has been drawn from a small group of patients whose EBV reactivations preceded HBV flares[35]. Sugawara et al[36] have shown in vitro that EBNA1 promotes HCV replication. Speculative viral or immune interference in cases of chronic hepatitis B or C and EBV infection needs further research.
Bertolini et al[37] investigated an experimental model (nu/nu mice) of chronic EBV hepatitis with typical intrasinusoidal lesions after inoculation of EBV-infected B-cells. The study provided evidence for EBV replication in a very rare proportion of hepatocytes. Despite lack of evidence, we might speculate that infection of non-lymphoid cells is possible via a specific integrin-dependant mechanism[38]. Hesitant reports have linked EBV to chronic hepatitis in non-immunocompromised humans. The existence of EBV-associated liver disease is still accepted with caution as EBV has not been detected in human hepatocytes[13]. Specific latent antigens as well as EBER transcripts are detected in infiltrating lymphocytes. It has been proposed that liver cells suffer from a form of collateral damage[13]. Chronic hepatitis might also be induced by a soluble Fas-ligand, tumor necrosis factor and IFN-?[39-41]. In most cases the infiltrating lymphocytes are CD8+ CTLs. It has also been found that activated CD8+ cells might be selectively trapped in the liver as they are bound to specific adhesive molecules expressed by Kupffer cells[42]. In the last year, several studies have tried to lift the curtain regarding chronic hepatitis associated with EBV infection. Drebber et al[43] proposed a list of criteria to establish the diagnosis: presence of suggestive histopathological features, serological profile and detection of viral genome in the liver tissue. In spite of some methodological limitations, this study addressed the necessity of new scoring systems regarding the possible EBV-associated chronic liver disease. Their work revived the interest in this issue both for pathologists and molecular hepatologists[43]. The critics of a hypothesis for chronic EBV liver disease in non-immunocompromised patients discuss so called “incidental virus” or amplification of the genome in circulating B cells which turn up in the liver. The existence of acute mononuclear hepatitis during primary EBV infection has been already accepted. Hence, it is most likely that the reactivation leading to liver damage occurs whether the infected lymphocytes are incidentally or intentionally in the liver. We previously discussed cases of EBV-associated chronic hepatitis in patients with reactivated EBV infection and increased specific CTL-response to a lytic EBV-epitope compared to healthy controls[44]. We presumed frequent reactivations in these patients because we had found an increased percentage of terminally differentiated CD28(-) CD27(-) CD8(+) T cells, suggestive of chronic antigen stimulation and replicative senescence. Diminished expression of co-stimulatory molecules CD28 and CD27 could further compromise CD8+ reactivation and characterize these terminally differentiated cells as more resistant to apoptosis[45,46]. Focused T-cell pull with low expression of CD28 and CD27 has low ability to control reactivations and is a typical finding in an elderly group. Surprisingly, very similar changes were found in younger patients under chronic cytomegalovirus and EBV antigen stimulation[47].
We surmise that a chronic liver disease might be a manifestation of a chronic EBV infection with frequent reactivations and persistent, moderate or low level of viral load. Based on recent studies and cases we can propose the expansion of Drebber’s criteria by adding recurrent EBV reactivations, increased circulating EBV-specific CTLs, and increased CD38 B-cell expression. We are also inclined to accept as additional clinical signs the increase of LDH levels, mild spleen enlargement and tendency for thrombocytopenia.
LIVER TRANSPLANTATION AND EBV INFECTION
EBV infection is the main cause of post-transplant lymphoproliferative disease (PTLD). The incidence of PTLD ranges from 0.5% to 30% depending on the organ being transplanted, the EBV status of the transplant recipient and donor, and the therapies used to achieve immunosuppression[48,49]. EBV seronegativity at the time of transplant and pediatric age are predisposing factors. The disorder occurs commonly in combined liver-kidney transplants, followed by cardiac, liver, lung, and then kidney transplants. In addition, constitutional factors such as cytokine gene polymorphism may play a predisposing role. Little is known about the chronic carrier state and its relation to late PTLD. Most pediatric liver transplant candidates are EBV-naïve when listed for orthotopic liver transplantation (OLT). Those immunosuppressed, EBV-naïve children, who receive an adult EBV-positive liver, are unable to adequately control EBV primary infection, hamper viral replication and avoid lymphoproliferation[50]. For this reason, PTLD has become one of the major threats in transplantation, complicating the course of up to 10% of pediatric liver graft recipients, with a mortality reported up to 50%[51]. All data support the recommendation of strict EBV monitoring in the first months after the transplantation. However, little is known about late and chronically persistent infection. Helpful insights into how often and how long we should monitor viremia during follow-up are insufficient. D'Antiga et al[52] revealed that none of their pre-OLT seropositive patients had sustained positivity of EBV serology or polymerase chain reaction (PCR) for 6 mo or longer, versus as many as 65% of those who were EBV-negative pre-OLT. A prolonged EBV viral load was strictly related to pre-OLT immunity against the virus and appeared to be associated with the occurrence of PTLD[52]. In fact, it is well established that persistence of EBV is a risk factor for development of lymphomas[53]. Patients who demonstrate a sustained viral detection are at risk for the development of late PTLD which implies necessity for preliminary testing as well as for long-term EBV infection follow-up. The development of molecular genetic diagnosis for EBV (PCR) means that progressive disease, or PTLD, may be prevented by preemptive reduction of immunosuppression in response to rising EBV titers.
EBV AND LIVER CANCER
EBV was the first human virus directly implicated in carcinogenesis. Since its discovery it has been considered as a major player in the development of a wide range of cancers both in immunocompetent and immunocompromised individuals. Recent studies have concluded EBV itself or infected cell clones might promote replication of the HCV[31,36]. Presumably, EBNA1 is responsible for supporting HCV replication, suggesting that EBV may be involved in the development of hepatocellular carcinoma (HCC)[54]. The detection of EBV gene products in HCC additionally supports this assumption. Sugawara et al[55] reported a higher amount of EBV DNA in HCV-positive HCC compared to HBV-associated HCC. EBV-infected cells support HCV replication better than uninfected cells, suggesting that EBV may act as a helper virus to promote HCV replication in the HCV-positive HCCs, especially in Japanese patients. Li et al[56] found that almost 30% of liver cancers harbored EBV DNA (vs 8% in the control group, P < 0.05) suggesting that the herpes virus might be involved in hepatocellular carcinogenesis in China. However, studies from Western countries do not confirm the hypothesis that EBV may promote the development of HCC. Akhter et al[57] examined cancer tissues of 31 non-cirrhotic, HCC patients. None of the tumor samples were found to be positive for EBV DNA. Being unable to confirm an association between EBV and infection with hepatitis viruses in HCC, the authors suggested environmental or genetic factors which could predispose Chinese and Japanese patients to develop EBV-infected HCC. On the other hand, a possible source of detected EBV DNA might be the infiltrating lymphocytes. Furthermore, a study from The Netherlands concluded that the absence of epithelial-specific BARF1 transcripts and other EBV transcripts and proteins in EBV DNA PCR-positive cases argues strongly against a role for EBV in HCC[58]. However, weak signals for EBV DNA in 5 of 16 HCCs (31.25%) and in two of four HCV-related hepatitis cases were detected and actually no EBV DNA was found in non-neoplastic and normal liver tissue, using DNA PCR-Enzyme Immunoassay for the detection of the BamHI W repeat fragment of EBV. The weak positivity of EBV DNA in some liver tissues was explained by amplification of EBV DNA in the lymphoid infiltrate or blood, reflecting a high EBV DNA load in these patients. Chen et al[59] showed that circulating EBV-positive peripheral B cells express BARF0 transcripts which could also explain the negative BamHI A rightward transcripts RNA in situ hybridization results. Moreover, we cannot exclude the presence of EBV-positive lymphocytes or EBER-positive hepatocytes in the larger amounts of tissue, as most studies usually test routine histology sections (5 ?m thick paraffin-embedded or cryosections). This fact raises the question whether usual techniques such as immunohistochemistry and in situ hybridization lack enough power to detect the virus in the liver regardless of its place of persistence - infiltrating lymphocytes, hepatocytes or Kupffer and other liver cells. We would welcome better evidence for or against the causative (and/or supportive) role of EBV in human HCC carcinogenesis.
Undeservedly neglected within hepatological society, EBV-associated chronic liver disease demonstrates the challenges in discovering the intimate mechanism of viral-host interactions leading to different clinical syndromes. Since proven to induce acute hepatitis during IM, to affect the liver in a PTLD setting, possibly to contribute to liver carcinogenesis, it would not be surprising if EBV causes chronic hepatitis. Undoubtedly, follow-up of patients is required to reveal the long-term complications of EBV-associated liver disease before we decide that this viral infection belongs in a group of meaningless companions of cryptogenic disease.
Footnotes
Peer reviewer: Jessica A Davila, PhD, Assistant Professor, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, 2002 Holcombe Blvd. (152), Houston, TX 77030, United States
S- Editor Wang YR L- Editor Logan S E- Editor Lin YP
References
1.
Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481-492.[PubMed] [DOI]
2.
Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol. 2005;6:873-879.[PubMed] [DOI]
3.
Maurmann S, Fricke L, Wagner HJ, Schlenke P, Hennig H, Steinhoff J, Jabs WJ. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol. 2003;41:5419-5428.[PubMed] [DOI]
4.
Rickinson AB, Kieff E. Epstein-Barr virus. In:Knipe DM, Howley PM, eds .,editors.Fields virology. 4th ed, Vol 2. Philadelphia: Lippincott Williams & Wilkins; 2001.pp.2575-2627.
5.
Babel N, Schwarzmann F, Prang N, Jaeger M, Wolf H, Kern F, Volk HD, Reinke P. Association between Epstein-Barr virus infection and late acute transplant rejection in long-term transplant patients. Transplantation. 2001;72:736-739.[PubMed] [DOI]
6.
Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995;89:98-103.[PubMed]
7.
Gleeson M, Pyne DB, Austin JP, Lynn Francis J, Clancy RL, McDonald WA, Fricker PA. Epstein-Barr virus reactivation and upper-respiratory illness in elite swimmers. Med Sci Sports Exerc. 2002;34:411-417.[PubMed] [DOI]
8.
Kieff E. Epstein-Barr virus and its replication. In:Fields BN, Knipe DM, Howley PM, eds .,editors.Fields virology. 3rd ed, Vol. 2. Philadelphia: Lippincott-Raven; 1996.pp.2343-2396.
9.
Kerr BM, Lear AL, Rowe M, Croom-Carter D, Young LS, Rookes SM, Gallimore PH, Rickinson AB. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology. 1992;187:189-201.[PubMed] [DOI]
10.
Crum NF. Epstein Barr virus hepatitis: case series and review. South Med J. 2006;99:544-547.[PubMed] [DOI]
11.
Cocuz ME, Idomir ME, Tic?u OC. [Clinical and biological aspects of liver damage in infectious mononucleosis]. Bacteriol Virusol Parazitol Epidemiol. 2003;48:177-181.[PubMed]
12.
Hinedi TB, Koff RS. Cholestatic hepatitis induced by Epstein-Barr virus infection in an adult. Dig Dis Sci. 2003;48:539-541.[PubMed] [DOI]
13.
Kimura H, Nagasaka T, Hoshino Y, Hayashi N, Tanaka N, Xu JL, Kuzushima K, Morishima T. Severe hepatitis caused by Epstein-Barr virus without infection of hepatocytes. Hum Pathol. 2001;32:757-762.[PubMed] [DOI]
14.
Edoute Y, Baruch Y, Lachter J, Furman E, Bassan L, Assy N. Severe cholestatic jaundice induced by Epstein-Barr virus infection in the elderly. J Gastroenterol Hepatol. 1998;13:821-824.[PubMed] [DOI]
15.
Papatheodoridis GV, Delladetsima JK, Kavallierou L, Kapranos N, Tassopoulos NC. Fulminant hepatitis due to Epstein-Barr virus infection. J Hepatol. 1995;23:348-350.[PubMed] [DOI]
16.
Markin RS, Linder J, Zuerlein K, Mroczek E, Grierson HL, Brichacek B, Purtilo DT. Hepatitis in fatal infectious mononucleosis. Gastroenterology. 1987;93:1210-1217.[PubMed]
17.
Feranchak AP, Tyson RW, Narkewicz MR, Karrer FM, Sokol RJ. Fulminant Epstein-Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Liver Transpl Surg. 1998;4:469-476.[PubMed] [DOI]
18.
Straus SE. The chronic mononucleosis syndrome. J Infect Dis. 1988;157:405-412.[PubMed]
19.
Shibuya A, Tsuchihashi T, Watanabe M, Nakazawa T, Takeuchi A, Sakurai K, Mitomi H, Saigenji K. Severe chronic active Epstein-Barr virus infection associated with multiple necrotic lesions in the liver. Hepatol Res. 2003;25:447-454.[PubMed] [DOI]
20.
Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100:4059-4066.[PubMed] [DOI]
21.
Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol. 2009;20:1472-1482.[PubMed] [DOI]
22.
Jaffe ES, Wilson WH. Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. Cancer Surv. 1997;30:233-248.[PubMed]
23.
Vento S, Cainelli F. Is there a role for viruses in triggering autoimmune hepatitis?. Autoimmun Rev. 2004;3:61-69.[PubMed] [DOI]
24.
Chiba T, Goto S, Yokosuka O, Imazeki F, Tanaka M, Fukai K, Takahashi Y, Tsujimura H, Saisho H. Fatal chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2004;16:225-228.[PubMed] [DOI]
25.
Nobili V, Comparcola D, Sartorelli MR, Devito R, Marcellini M. Autoimmune hepatitis type 1 after Epstein-Barr virus infection. Pediatr Infect Dis J. 2003;22:387.[PubMed] [DOI]
26.
Vento S, Guella L, Mirandola F, Cainelli F, Di Perri G, Solbiati M, Ferraro T, Concia E. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet. 1995;346:608-609.[PubMed] [DOI]
27.
Kojima K, Nagayama R, Hirama S, Maeda T, Takikawa H, Miyake K, Yamanaka M, Shiga J. Epstein-Barr virus infection resembling autoimmune hepatitis with lactate dehydrogenase and alkaline phosphatase anomaly. J Gastroenterol. 1999;34:706-712.[PubMed] [DOI]
28.
Aceti A, Mura MS, Babudieri S, Bacciu SA. A young woman with hepatitis after a sore throat. Lancet. 1995;346:1603.[PubMed] [DOI]
29.
Biest S, Schubert TT. Chronic Epstein-Barr virus infection: a cause of granulomatous hepatitis?. J Clin Gastroenterol. 1989;11:343-346.[PubMed] [DOI]
30.
Kikuchi K, Miyakawa H, Abe K, Fujikawa H, Horiuchi T, Nagai K, Kako M. Vanishing bile duct syndrome associated with chronic EBV infection. Dig Dis Sci. 2000;45:160-165.[PubMed] [DOI]
31.
Petrova M, Kamburov V, Nikolovska D, Kosseva O, Nikolova M, Krastev Z. Epstein-Barr virus: is there any contribution to chronic hepatitis B and C?. Liver Int. 2010;30:488-489.[PubMed] [DOI]
32.
Jabs WJ, Wagner HJ, Schlenke P, Kirchner H. The primary and memory immune response to Epstein-Barr virus infection in vitro is characterized by a divergent production of IL-1beta/IL-6 and IL-10. Scand J Immunol. 2000;52:304-308.[PubMed] [DOI]
33.
Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C, Davis GL. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology. 2003;38:859-868.[PubMed] [DOI]
34.
Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284:825-829.[PubMed] [DOI]
35.
Santolamazza M, Marinelli RM, Bacosi M, D'Innocenzo S, Miglioresi L, Patrizi F, Delle Monache M, Ricci GL. What kind of hepatitis?. J Int Med Res. 2001;29:441-444.[PubMed]
36.
Sugawara Y, Makuuchi M, Kato N, Shimotohno K, Takada K. Enhancement of hepatitis C virus replication by Epstein-Barr virus-encoded nuclear antigen 1. EMBO J. 1999;18:5755-5760.[PubMed] [DOI]
37.
Bertolini L, Iacovacci S, Bosman C, Carloni G, Monaco V, Bangrazi C, Serafino A, Gualandi G, Prantera G, Fruscalzo A. Low cell dosage of lymphoblastoid human cell lines EBV(+) is associated to chronic hepatitis in a minority of inoculated Nu/Nu mice. J Med Virol. 2002;66:70-81.[PubMed] [DOI]
38.
Tugizov SM, Berline JW, Palefsky JM. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med. 2003;9:307-314.[PubMed] [DOI]
39.
Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med. 1997;3:409-413.[PubMed] [DOI]
40.
Küsters S, Gantner F, Künstle G, Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology. 1996;111:462-471.[PubMed] [DOI]
41.
Bradham CA, Plümpe J, Manns MP, Brenner DA, Trautwein C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol. 1998;275:G387-G392.[PubMed]
42.
Mehal WZ, Juedes AE, Crispe IN. Selective retention of activated CD8+ T cells by the normal liver. J Immunol. 1999;163:3202-3210.[PubMed]
43.
Drebber U, Kasper HU, Krupacz J, Haferkamp K, Kern MA, Steffen HM, Quasdorff M, Zur Hausen A, Odenthal M, Dienes HP. The role of Epstein-Barr virus in acute and chronic hepatitis. J Hepatol. 2006;44:879-885.[PubMed] [DOI]
44.
Petrova M, Muhtarova M, Nikolova M, Magaev S, Taskov H, Nikolovska D, Krastev Z. Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients. World J Gastroenterol. 2006;12:5711-5716.[PubMed]
45.
van Baarle D, Tsegaye A, Miedema F, Akbar A. Significance of senescence for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system. Immunol Lett. 2005;97:19-29.[PubMed] [DOI]
46.
Dunne PJ, Faint JM, Gudgeon NH, Fletcher JM, Plunkett FJ, Soares MV, Hislop AD, Annels NE, Rickinson AB, Salmon M. Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood. 2002;100:933-940.[PubMed] [DOI]
47.
Wills MR, Okecha G, Weekes MP, Gandhi MK, Sissons PJ, Carmichael AJ. Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8(+) T cell response. J Immunol. 2002;168:5455-5464.[PubMed]
48.
Randhawa PS, Markin RS, Starzl TE, Demetris AJ. Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients. Clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol. 1990;14:538-547.[PubMed] [DOI]
49.
Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant. 2002;6:456-464.[PubMed] [DOI]
50.
McDiarmid SV. Management of the pediatric liver transplant patient. Liver Transpl. 2001;7:S77-S86.[PubMed] [DOI]
51.
Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant. 2002;6:280-287.[PubMed] [DOI]
52.
D'Antiga L, Del Rizzo M, Mengoli C, Cillo U, Guariso G, Zancan L. Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transpl. 2007;13:343-348.[PubMed] [DOI]
53.
Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350:1328-1337.[PubMed] [DOI]
54.
Sugawara Y, Makuuchi M, Takada K. Detection of Epstein-Barr virus DNA in hepatocellular carcinoma tissues from hepatitis C-positive patients. Scand J Gastroenterol. 2000;35:981-984.[PubMed] [DOI]
55.
Sugawara Y, Mizugaki Y, Uchida T, Torii T, Imai S, Makuuchi M, Takada K. Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Virology. 1999;256:196-202.[PubMed] [DOI]
56.
Li W, Wu BA, Zeng YM, Chen GC, Li XX, Chen JT, Guo YW, Li MH, Zeng Y. Epstein-Barr virus in hepatocellular carcinogenesis. World J Gastroenterol. 2004;10:3409-3413.[PubMed]
57.
Akhter S, Liu H, Prabhu R, DeLucca C, Bastian F, Garry RF, Schwartz M, Thung SN, Dash S. Epstein-Barr virus and human hepatocellular carcinoma. Cancer Lett. 2003;192:49-57.[PubMed] [DOI]
58.
zur Hausen A, van Beek J, Bloemena E, ten Kate FJ, Meijer CJ, van den Brule AJ. No role for Epstein-Barr virus in Dutch hepatocellular carcinoma: a study at the DNA, RNA and protein levels. J Gen Virol. 2003;84:1863-1869.[PubMed] [DOI]
59.
Chen H, Smith P, Ambinder RF, Hayward SD. Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood. Blood. 1999;93:3026-3032.[PubMed]